kellyb
Penultimate Amazing
- Joined
- Jan 18, 2006
- Messages
- 12,632
My numbers come from the CDC. It's on their Mumps "technical information" page...and, they're sending all their info to the Iowa DOH page, which also gives the "the vaccine is 95% effective" stories of how there are 100 students, five are not immune coz the vax didn't take, so the virus spreads.Where did your numbers and information come from? My understanding is the ACIP claims 90% with first dose and 95% with the second and the numbers come from seroprevalence studies done when measles started reappearing in the early 90s.
But on the Mumps "technical information" page in the "epidemic update" section, it says one dose is 70-80% effective, and in the conference the CDC director had a couple of weeks ago she was insisting the vaccine had no problems, and in the teleconference with their chick in charge of viral diseases, she said the vaccine effectiveness was so low it probably wouldn't turn up on titre checks.
This is all on the CDC's website.
ETA:
http://www.cdc.gov/nip/diseases/mumps/mumps-tech-faqs.htm
In one study 86.6% of vaccinees had evidence of mumps seroconversion at 4 weeks after immunization and 93.3% had evidence of seroconversion after 5 weeks.
http://www.cdc.gov/nip/diseases/mumps/mumps-tech-faqs.htm
http://www.idph.state.ia.us/adper/common/pdf/mumps/explaining_effectiveness.pdfThe vaccine effectiveness for one dose of MMR is 70-80% and 80-90% for two doses.
The mumps vaccine (part of the MMR vaccine) is about 95% effective.
• This means out of every 100 people vaccinated, 95 will be protected. However, the vaccine will not “take” in 5 people, and these people will remain susceptible to the disease.
• By comparison, the measles vaccine (also part of the MMR vaccine) is about 98% effective and the annual influenza vaccine is about 70-85% effective.
http://www.cdc.gov/nip/diseases/mumps/control-hcw.htm
https://www.merckvaccines.com/proquadProductPage_frmst.htmlSerologic evidence of immunity (i.e., positive mumps IgG):
In unvaccinated persons or persons with a history of mumps disease, presence of mumps specific antibodies should be considered evidence of natural infection and immunity. However, a history of physician-diagnosed mumps is considered reliable proof of immunity and antibody testing of such individuals is not recommended.
Results of serum antibody tests in vaccinated persons are difficult to interpret and such testing is NOT recommended. In vaccinated persons, antibody levels are often lower than following natural infection, and commercially available tests may not detect such low levels of antibody. In addition, there is no data that correlates levels of serum antibody with protection from disease. Last, there are no data on the impact of additional (greater than two) doses of mumps vaccine on antibody levels or protection from disease.
http://www.merck.com/mrkshared/mmanual/section19/chapter256/256f.jsp#A019-256-0178First-dose immune response rates with ProQuad administered to children 12–23 months of age*
Mumps- 95.8%-98.8%
Efficacy of measles, mumps, rubella, and varicella components was previously established in a series of clinical studies with the monovalent vaccines; a high degree of protection from infection was demonstrated in these studies.
Mumps (see also Mumps under Viral Infections in Ch. 265): Live mumps vaccine produces protective antibodies in 95% of those vaccinated
http://www.merck.com/mrkshared/CVMH...d=immunization&domain=www.merck.com#hl_anchor
Live mumps virus vaccine is the agent of choice for active immunization (see Childhood Immunizations in Ch. 256). This vaccine produces no significant local or systemic reaction and requires only one injection.
And editing in to add the stuff about exactly how effective a mumps vax needs to be for it to not result in a disease burdon shift into an older age group:
http://www.who.int/vaccines/en/mumps.shtml
http://www.vhpb.org/files/html/Meet...doc/A5EQuestionsandAnswersonVaccineSafety.pdfNational decisions to implement large-scale mumps vaccination should be based on careful cost-benefit analyses. As insufficient childhood vaccination coverage may result in an unfortunate epidemiological shift in the incidence of mumps to older age groups, childhood mumps vaccination should aim at a 80% coverage rate, or higher.
http://www.pitt.edu/~super1/lecture/lec1181/017.htmFor example, insufficient childhood mumps vaccination coverage (below
80%) may result in an undesirable epidemiological shift in the incidence of mumps to older
age groups
http://www.pitt.edu/~super1/lecture/lec1181/018.htm
Nevertheless, there is also a risk: because of the phenomenon of herd immunity, under certain circumstances, a vaccination programme can do more harm than good on a population basis.
This might arise if a/ the target disease has more severe clinical consequences in adults than in children, and b/ the vaccination coverage achieved is below a certain threshold (the "sorcerer’s apprentice" situation).
Such diseases include rubella, chickenpox, mumps, hepatitis A.
Last edited: